Literature DB >> 9717416

Overview of operations for morbid obesity.

M Deitel1.   

Abstract

Massive obesity is prevalent and associated with serious comorbidities. For patients who cannot sustain weight loss, malabsorption and gastric reduction operations have been developed. Patients with the former operation require surveillance for protein malnutrition and other sequelae; those with gastric reduction require a permanent tiny reservoir and stoma. Long-term follow-up surveillance is necessary. Postoperatively, 15% to 40% of patients, depending on the operative procedure performed, fail to maintain adequate weight loss. Successful weight loss in most of these patients makes this challenging surgery worthwhile, with alleviation of devastating disease and marked improvement in quality of life.

Entities:  

Mesh:

Year:  1998        PMID: 9717416     DOI: 10.1007/s002689900494

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  11 in total

1.  Galen on obesity: etiology, effects, and treatment.

Authors:  Niki S Papavramidou; Spiros T Papavramidis; Helen Christopoulou-Aletra
Journal:  World J Surg       Date:  2004-06       Impact factor: 3.352

Review 2.  Potential of surgery for curing type 2 diabetes mellitus.

Authors:  Francesco Rubino; Michel Gagner
Journal:  Ann Surg       Date:  2002-11       Impact factor: 12.969

3.  Quality of life following laparoscopic gastric banding in patients with morbid obesity.

Authors:  S M Freys; H Tigges; J Heimbucher; K H Fuchs; M Fein; A Thiede
Journal:  J Gastrointest Surg       Date:  2001 Jul-Aug       Impact factor: 3.452

4.  Results of gastric bypass plus resection of the distal excluded gastric segment in patients with morbid obesity.

Authors:  Attila Csendes; Patricio Burdiles; Karin Papapietro; Juan Carlos Diaz; Fernando Maluenda; Ana Burgos; Jorge Rojas
Journal:  J Gastrointest Surg       Date:  2005-01       Impact factor: 3.452

5.  Ghrelin and apolipoprotein AIV levels show opposite trends to leptin levels during weight loss in morbidly obese patients.

Authors:  E Pardina; M D López-Tejero; R Llamas; R Catalán; R Galard; H Allende; V Vargas; A Lecube; J M Fort; J A Baena-Fustegueras; J Peinado-Onsurbe
Journal:  Obes Surg       Date:  2009-01-27       Impact factor: 4.129

6.  Ala55Val polymorphism on UCP2 gene predicts greater weight loss in morbidly obese patients undergoing gastric banding.

Authors:  Hsin-Hung Chen; Wei-Jei Lee; Weu Wang; Ming-Te Huang; Yi-Chih Lee; Wen-Harn Pan
Journal:  Obes Surg       Date:  2007-07       Impact factor: 4.129

7.  Clinical characteristics and outcome of morbidly obese bariatric patients with concurrent hepatitis B viral infection.

Authors:  Wei-Jei Lee; Weu Wang; Yi-Chih Lee; Ming-Te Huang
Journal:  Obes Surg       Date:  2008-05       Impact factor: 4.129

8.  Impact of laparoscopic adjustable gastric banding on obesity co-morbidities in the medium- and long-term.

Authors:  M Korenkov; S Shah; S Sauerland; F Duenschede; Th Junginger
Journal:  Obes Surg       Date:  2007-05       Impact factor: 4.129

9.  Laparoscopic mini-gastric bypass: experience with tailored bypass limb according to body weight.

Authors:  Wei-Jei Lee; Weu Wang; Yi-Chih Lee; Ming-Te Huang; Kong-Han Ser; Jung-Chien Chen
Journal:  Obes Surg       Date:  2008-01-12       Impact factor: 4.129

Review 10.  Intragastric balloon for obesity.

Authors:  M Fernandes; A N Atallah; B G O Soares; S Humberto; S Guimarães; D Matos; L Monteiro; B Richter
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.